GT
RPRX icon

Glenmede Trust’s Royalty Pharma RPRX Stock Holding History

Glenmede Trust’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Sell
7,184
-628
-8% -$32.7K ﹤0.01% 1064
2026
Q1 		$375K Buy
7,812
+254
+3% +$11.1K ﹤0.01% 1067
2025
Q4 		$292K Buy
+7,558
New +$288K ﹤0.01% 1151
2025
Q1 		– Sell
-83,266
Closed -$2.12M – 1432
2024
Q4 		$2.12M Buy
83,266
+33,687
+68% +$893K 0.01% 540
2024
Q3 		$1.4M Sell
49,579
-198,419
-80% -$5.5M 0.01% 638
2024
Q2 		$6.54M Sell
247,998
-156,381
-39% -$4.33M 0.03% 410
2024
Q1 		$12.3M Buy
404,379
+221,182
+121% +$6.52M 0.06% 329
2023
Q4 		$5.15M Sell
183,197
-318,483
-63% -$8.75M 0.03% 424
2023
Q3 		$13.6M Buy
501,680
+465,063
+1,270% +$13.8M 0.08% 264
2023
Q2 		$1.32M Hold
36,617
– – 0.01% 591
2023
Q1 		$1.32M Buy
36,617
+971
+3% +$36K 0.01% 592
2022
Q4 		$1.41M Buy
35,646
+5,410
+18% +$226K 0.01% 585
2022
Q3 		$1.21M Buy
+30,236
New +$1.29M 0.01% 605
2022
Q2 		– Sell
-17,761
Closed -$691K – 1362
2022
Q1 		$691K Buy
+17,761
New +$697K ﹤0.01% 813
2021
Q4 		– Sell
-21,108
Closed -$762K – 1364
2021
Q3 		$762K Sell
21,108
-1,258
-6% -$48.9K ﹤0.01% 778
2021
Q2 		$916K Sell
22,366
-7,512
-25% -$320K ﹤0.01% 726
2021
Q1 		$1.3M Buy
29,878
+7,518
+34% +$356K 0.01% 620
2020
Q4 		$1.12M Buy
+22,360
New +$949K 0.01% 633

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's RPRX Position: Q2 2026 in Review

Glenmede Trust reduced its Royalty Pharma (RPRX) stake by 8% in Q2 2026, selling an estimated $32.7K and leaving 7,184 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #1064.

Glenmede Trust first reported a position in RPRX in Q4 2020 and has held it in 18 quarters since. The position peaked at $13.6M in Q3 2023. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Glenmede Trust held 7,184 shares of Royalty Pharma worth $403K as of Q2 2026.
  • Glenmede Trust sold 628 Royalty Pharma shares in Q2 2026, an estimated $32.7K.
  • Royalty Pharma made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1064 holding.
  • Glenmede Trust first reported a position in Royalty Pharma in Q4 2020 and has held it in 18 quarters since.
  • Glenmede Trust's Royalty Pharma position peaked at $13.6M in Q3 2023.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.